FULL PAPER

Prophylactic radiotherapy against heterotopic ossification following internal fixation of acetabular fractures: a comparative estimate of risk

[1]N G BURNET, FRCR, MD, [2]P NASR, FRCS, [2]G YIP, MRCS, [1]J E SCAIFE, MRCP, FRCR, [3]T HOUSE, BPharm,
[4]S J THOMAS, PhD, [5]F HARRIS, MRCP, FRCR, [2]P J OWEN, FRCS and [2]P HULL, FRCS

[1]Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
[2]Department of Orthopaedics and Trauma, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
[3]Medicines Information Department, Pharmacy Department, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK
[4]Medical Physics Department, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
[5]Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Address correspondence to: Professor Neil G. Burnet
E-mail: ngb21@cam.ac.uk

Objective: Radiotherapy (RT) is effective in preventing heterotopic ossification (HO) around acetabular fractures requiring surgical reconstruction. We audited outcomes and estimated risks from RT prophylaxis, and alternatives of indometacin or no prophylaxis.
Methods: 34 patients underwent reconstruction of acetabular fractures through a posterior approach, followed by a 8-Gy single fraction. The mean age was 44 years. The mean time from surgery to RT was 1.1 days. The major RT risk is radiation-induced fatal cancer. The International Commission on Radiological Protection (ICRP) method was used to estimate risk, and compared with a method (Trott and Kemprad) specifically for estimating RT risk for benign disease. These were compared with risks associated with indometacin and no prophylaxis.

Results: 28 patients (82%) developed no HO; 6 developed Brooker Class I; and none developed Class II–IV HO. The ICRP method suggests a risk of fatal cancer in the range of 1 in 1000 to 1 in 10,000; the Trott and Kemprad method suggests 1 in 3000. For younger patients, this may rise to 1 in 2000; and for elderly patients, it may fall to 1 in 6000. The risk of death from gastric bleeding or perforation from indometacin is 1 in 180 to 1 in 900 in older patients. Without prophylaxis risk of death from reoperation to remove HO is 1 in 4000 to 1 in 30,000.
Conclusion: These results are encouraging, consistent with much larger series and endorse our multidisciplinary management. Risk estimates can be used in discussion with patients.
Advances in knowledge: The risk from RT prophylaxis is small, it is safer than indometacin and substantially overlaps with the range for no prophylaxis.

Heterotopic ossification (HO) can develop around surgically reconstructed acetabular fractures or hip replacements and is an important cause of morbidity. Radiotherapy (RT) has an established place in prophylaxis against HO.[1–10] We have developed a systematic multidisciplinary approach to the management of patients with traumatic acetabular fractures. The fractures are reconstructed surgically, and when a posterior surgical approach to the acetabulum has been used, this is followed by RT prophylaxis. This development has been prompted in part by the rising number of patients with traumatic acetabular fracture presenting here, especially since the designation of our centre as a major trauma centre in 2012. Most of these fractures are the result of road traffic accidents (RTAs), which are the commonest cause by far.[11]

Operative fixation of displaced acetabular fractures with open reduction and internal fixation has become the standard surgical management approach to these fractures,[12] and overall, outcomes are improving.[13] HO is a particular complication of posterior acetabular fractures, and a posterior surgical approach is an important additional risk factor.[14] However, this may be the optimum approach to reduce displaced fragments and to achieve the best possible anatomical restoration.

The most common symptoms and signs of HO are decreased range of movement and pain. More severe HO can lead to loss of joint mobility with decreased function, and the hip may even become ankylosed. In these circumstances, it is occasionally necessary to remove the heterotopic bone, although full excision of the abnormal bone is

extremely difficult and is associated with unacceptable complications such as poor abductor function and abnormal gait. This is a clinical outcome worth avoiding whenever possible.

HO is most commonly quantified using the Brooker classification system.[15] This scores severity from zero to IV, where Class IV represents ankylosis of the joint, and correlates well with functional outcome.[16] The incidence of HO ranges from 2% to 59%,[13–15,17] with severe HO rates of 15%, 21% and 38% in three series of patients following surgical reconstruction of acetabular fractures where prophylaxis was not used.[7,8,18] A meta-analysis of 3670 fractures found an overall risk of 26%, with significant HO (Class III or IV) occurring in 6%, and in the majority (2173 patients), prophylaxis was either not used or not documented.[17] However, the risk of grade III and IV HO is higher with the Kocher–Langenbeck (posterior) surgical approach, and this was specifically reported in the meta-analysis, which suggested a risk of severe HO of 12%.[17] This may be the most relevant figure for comparison with our results.

Patients with fractures resulting from RTAs may have a number of other associated injuries. Some of these, including head injuries, may further add to the risk of developing HO.[19] Such injuries also add to the complexity of management. Ventilated patients, for example, may be considered more appropriate for post-reconstruction prophylaxis using indometacin rather than RT. An additional issue is that many patients of RTA are relatively young, raising the question of risk vs benefit from the use of prophylaxis involving ionizing radiation.

The particular issue of risk from RT prompted us to review our overall management approach. The first step was to audit the outcome of patients treated with our multidisciplinary approach using post-operative RT, to ensure that our results matched other larger series. We also reviewed the published information on the efficacy of the two established methods of prophylaxis, RT and indometacin. We then sought to consider the potential risks of RT prophylaxis and to estimate the risks compared with the alternatives of indometacin treatment and no prophylaxis. We present and discuss these estimates of risk.

METHODS AND MATERIALS
Audit of heterotopic ossification outcomes
The review of outcomes was registered with the audit department. Data were obtained and analysed in accordance with hospital guidelines. Between 1997 and 2012, 57 patients had RT for HO prophylaxis in Addenbrooke's Hospital, Cambridge, UK. Of these, 39 patients had undergone surgery for posterior fractures of the acetabulum. 31 patients were treated from 2005 onwards, averaging just <4 per year, although this number appears to be rising, possibly related to major trauma centre designation.

In affected patients, HO increases post-operatively, typically reaching its maximum by about 12 weeks following surgery.[6,8,18] 34 of the 39 patients had plain radiographs taken 12 weeks or more after surgery and so were suitable for evaluation. The remaining five were lost to follow-up, which is a hazard with patients of RTAs who may not live locally. 25 patients (74%) were males and 9 (26%) were females. The mean age was

44 years (Figure 1). RTAs were the cause of trauma in 85% of patients. One fracture was the result of a rugby injury, one patient fell from scaffolding, one tripped and fell and in two patients, the cause of trauma was not recorded. 25 (74%) patients sustained 1 or more other injuries, including 2 with head injuries.

All 34 patients had major fractures with or without dislocation requiring surgical reconstruction, aimed at restoring anatomical integrity. This allows early mobilization, reduced morbidity and quicker discharge and also improves the long-term outlook.[18,20] Surgery was carried out as soon as the patient was stable following the injury (mean, 6 days; range, 0–17 days). In all patients, a posterior Kocher–Langenback approach was used to provide optimal access for the reconstruction, and since it is this group who have a particularly high risk of developing HO, RT was given post-operatively. The mean time from surgery to RT was 1.1 days (range, 1–5 days). The presence and severity of HO was assessed using the Brooker et al[15] grading system on the latest plain (anteroposterior) pelvis radiograph. The average time to the latest follow-up plain radiograph was 110 weeks (range, 13–534 weeks). None of the patients was pregnant when treated.

Five additional patients were originally intended to have RT: four had other injuries sufficiently serious to preclude RT and the fifth could not be treated with RT within 96 h, he/she was treated with indometacin instead and did not develop HO. Where RT prophylaxis is not possible, and provided there are no contraindications, we used 25 mg of indometacin three times a day for 6 weeks as an alternative.

The remaining 18 patients (of the 57) had all developed HO and received RT following excision or revision surgery. 3 received RT following surgery to remove heterotopic bone, which had formed around traumatic femoral fractures; 14 were treated following revision hip replacement and 1 after revision total knee replacement, where HO had developed after the original procedure. They will not be considered further here.

Radiotherapy technique
RT was planned from CT using ProSoma® virtual simulator software (Oncology Systems Limited, Shrewsbury, UK), except for the first few patients for whom a conventional simulator was used. The CT demonstrates the surgical reconstruction and is therefore routinely passed to the hospital picture archiving and communication system for review by the surgical team. The axial CT can also show the position of the ovary in premenopausal females, allowing confirmation that treatment avoids the ipsilateral ovary.

Anterior and posterior opposed fields are used, with the central axis closer to the medial field border to reduce divergence medially. The target includes the acetabular fracture, the musculature proximal to the greater trochanter, including the gluteus minimus,[21] the lesser trochanter and the muscle tissue lateral to the femur, excluding the skin laterally. Multileaf collimator shielding is used to reduce the volume treated and especially to minimize dose to the pelvic contents and external genitalia. Similar fields are reported in other studies.[10,22] Figure 2 shows an example of a case in which RT prophylaxis was not given as the

Figure 1. Frequency distribution of age of the 34 treated patients. Mean age was 44.4 years; median, 41.5 years; range, 21–72 years. Note that 15 (44%) were aged under 40 years.

Age distribution of patients treated

result of severe additional injuries. The distribution of the HO is useful in identifying the target volume for treatment. HO can also develop in the musculature lateral to the greater trochanter.[22] The area posterior to the hip joint and neck of the femur is also at risk. Indeed, a previous report described a technique to shield the femoral head in the hope of reducing late arthritis.[22] However, HO developed in 48% of the shielded hips, compared with 20% of those not shielded, so this is not recommended.

Figure 3 shows the RT planning images for a patient who had reconstruction of posterior wall fractures from a RTA. Treatment was planned and delivered the day after surgical reconstruction, which has the advantage that the fracture is stabilized and any traction has been removed. The field shown in Figure 3 is defined as the 50% isodose and must make some allowance for variation in set up on the linac. Our standard practice is to perform an electronic portal image of the anterior field before treatment and to correct a discrepant position with an action level of 0.5 cm. Testicular shielding has been recommended by some,[23] but we prefer to avoid placing uncomfortable bulky additional shielding between the legs, which could adversely affect patient positioning.

Figure 2. Pelvic radiographs of a 37-year-old patient who suffered a fracture dislocation of the left hip requiring reconstruction. Multiple other injuries, including pneumothorax and compound fractures at the knee, precluded early post-operative radiotherapy (RT), which would otherwise have been recommended. No alternative prophylaxis was given. (a) Post-operative film. Skin sutures and a catheter can be seen. (b) Follow-up film at 14 months, with Brooker grade IV heterotopic ossification (HO). This was evident within weeks of the reconstruction. Note the spur of HO extending from the acetabulum to ankylose the joint (arrowed). HO had also formed posteriorly and can be seen in projection just above the lesser trochanter. (c) 8 months following revision total hip replacement, performed at 19 months, with prophylactic RT delivered the following day. No HO has reformed.

Figure 3. (a) Digitally reconstructed radiograph showing the radiotherapy anterior field projection, in a young female with a complex posterior acetabular fracture dislocation requiring reconstruction, following a road traffic accident. The ovary, fully shielded, is shown medial to the treatment field. (b) Coronal CT reconstruction with the projection at depth of the anterior treatment field with corner multileaf collimator shielding, and ovary contour.

A standard single dose of 8 Gy (central axis mid-plane) is delivered with a linear accelerator, with an energy of 6, 10 or 15 MV, with one of the higher energies preferred for larger patients. At the beginning of the prophylactic RT programme, a dose of 8 Gy, rather than 7 Gy, was chosen in order to harmonize with other single fraction treatments, especially those given for bone metastases, for which 8 Gy is a widely used and evidence-based dose. We prefer to plan and treat the patient the day after surgical reconstruction to minimize the delay (see below). Typically, the patient is more comfortable and confident in moving from bed to scanner and treatment couch following reconstruction. RT is more traumatic prior to the fracture being reconstructed, and the timing of surgery is sometimes unpredictable. We therefore prefer to give early RT postoperatively; the reverse is true for revision hip replacement prophylaxis, when pre-operative RT is more comfortable and convenient for the patient.

Although non-union can occur with RT, this is less relevant where internal reconstruction has been performed and can also occur with indometacin.[23,24] RT does not affect healing of other fractures, unlike systemic indometacin.[24]

Estimates of risk

We sought to estimate the risk of fatal complications from three potential treatment strategies, namely RT prophylaxis, prophylaxis with indometacin and no prophylaxis. The most important risk associated with RT for HO is fatal radiation-induced cancer. However, a risk of death is also associated with indometacin therapy, even of short duration, particularly from gastrointestinal complications. In addition, there is a (small) risk of death associated with reoperation in patients who go on to develop severe HO. We have not attempted to address the non-fatal side effects or to estimate the effects of HO on quality of life.

Estimating risk from radiotherapy

A method to estimate the risk of fatal radiation-induced malignancy over the lifetime of the patient is provided by the International Commission on Radiological Protection (ICRP).[25] It is based largely on epidemiological studies of individuals exposed to whole-body low-dose irradiation, particularly survivors at Hiroshima and Nagasaki, and provides an estimate of global population risk, irrespective of age. However, this is designed explicitly for use in protection. Although not intended for application to the risks from therapeutic exposure, it does provide a methodology that considers different tissues and different volumes of tissue. The method involves calculating the mean organ dose for relevant organs at risk, multiplying this by an organ weighting factor,[25] summing these and finally multiplying by the recommended risk factor. We assumed an exposure of 8 Gy to 2% of the bone marrow and bone surface and 1% of the skin and muscle, with ICRP tissue weighting factors of 0.12 for the marrow and 0.01 for the other tissues. The risk factor is normally quoted as 5% per sievert (Sv).[25] However, this applies to the whole population, including children, and the ICRP suggests a risk factor of 4.1% per Sv for an adult population. However, the ICRP method is explicitly not intended for prediction of risks from therapeutic radiation,[25] and, moreover, it is thought to overestimate the risk, possibly by as much as 1–2 orders of magnitude.[26,27] We have not attempted to model scattered doses.[28]

Another approach is to consider the number of cases of malignancy in patients treated with RT, for either malignant or benign tumours, although most series relate to treatment of malignancy. Case reports of malignancy related to RT for HO prophylaxis, whilst important, do not provide estimates of incidence since no denominator of unaffected cases can be provided.

Trott and Kamprad[26] developed a procedure specifically for estimating cancer risks after RT of non-malignant diseases by using direct evidence derived from epidemiologic data in patients who were treated using irradiation in the past. They included allowance for field size and modifying factors, such as risk genes like retinoblastoma, to produce risk estimates relevant to clinical situations such as RT prophylaxis against HO.

The difference in risk for different ages at exposure is difficult to assess, although few data are available from the National

Research Council of the National Academies BEIR VII Phase 2 report.[29] This comprises data on estimates of risk of death from cancer attributable to whole-body radiation exposure according to the age at exposure, from birth to an age of 80 years. The most relevant data relate to the risks of "other" tumours, which exclude central pelvic and thoracic tumours, and breast cancer.

Estimating the risk from use of indometacin
Estimates of risk are based on published series of patients taking indometacin, or similar drugs, who develop complications, often concentrating on older patients who are at higher risk. We sought reports that might provide risk estimates, although we have not undertaken a systematic literature review. These have been combined with surgical estimates of the risk of death from the known major gastrointestinal complications of perforation and haemorrhage.

Estimating the risk from use of no prophylaxis
Although slightly artificial, a risk of death can be considered to exist for patients who develop severe HO, since a proportion may require further surgery to reduce morbidity, carrying a risk of perioperative death. Estimates are based on the incidence of severe HO, the proportion requiring surgery and estimates of risk for elective surgery.

RESULTS AND DISCUSSION
Results of clinical series
In our small series of 34 patients, plain radiographs demonstrated that 28 (82%) patients developed no HO. Six patients (18%) developed Brooker Class I HO, and none developed Class II, III or IV. One of the patients with Brooker Class I HO had the additional risk factor of an associated head injury. These results compare favourably with the published risk of severe HO of 1 in 8 (12%) patients requiring a posterior surgical approach,[17] even though our series is small. As noted above, five patients were unable to receive RT: two received indometacin; one remaining free from HO; the other developing grade III HO; and three had no prophylaxis and developed grades I, III and IV HO. This provides endorsement for the use of prophylaxis, as discussed below.

Radiotherapy and indometacin as prophylaxis against heterotopic ossification
The clinical features of ankylosis and reduced function only appear in grade III and above. Therefore, prophylactic therapy is aimed at reducing significant HO of a higher degree.[16] Timing and dose of prophylactic RT have been established over some years, with large randomized controlled trials providing robust data. Early reports of RT as HO prophylaxis typically used modest doses such as 20 Gy in ten fractions, similar to schedules known to impair bone growth.[1] In historical cohorts, 10 Gy in five fractions was found to be as effective as 20 Gy in ten fractions.[2] A randomized trial of post-operative RT demonstrated no difference between 10.0 Gy in five fractions and 17.5 Gy in five fractions,[4] endorsing the lower dose. Subsequent studies have shown that single fractions are just as effective, provided doses of $\geq$7 Gy are used.[2,3,5,10]

No difference in outcome was found in patients randomized to pre-operative RT (less than or equal to 4 h before surgery) or post-operative RT (less than or equal to 96 h post-operative).[4] However, delays beyond 3–4 days have higher rates of HO,[7] with rates rising dramatically for delays of more than 3 weeks.[10]

Indometacin has also been used for prophylaxis but appears less effective. In a randomized trial, 301 patients received post-operative RT with either 5 or 7 Gy or indometacin.[5] Overall rates of HO were 30.1%, 11.1% and 16.0%, respectively. Statistically, 5 Gy was the least effective, and 7 Gy and non-steroidal anti-inflammatory drug (NSAID) were equivalent. However, for HO grades III and IV, 7 Gy was significantly more effective than NSAID, although both treatments had low rates (0% vs 1.7%). Rates of severe HO after surgery and RT of 9% compared with 18% for indometacin[6] and 4% vs 11%[8] have been reported. 16 patients who did not receive prophylaxis all developed HO, 38% with grade III or IV.[8] In a meta-analysis based on 5 prospective studies, describing 384 patients, the incidence of grade III and IV HO was significantly lower in patients treated with RT (3%, 5 of 160) than in those who received indometacin (9%, 20 of 224) ($p = 0.04$).[9]

There is evidence of efficacy of NSAIDs in preventing HO after hip arthroplasty, with a suggested reduction in risk of HO after hip arthroplasty of a half to two-thirds.[30,31] However, there are some clear reports of lack of efficacy after reconstruction of acetabular fractures.[18,31–33] In a randomized study of a 6-week course of indometacin or no prophylaxis in 107 patients, no statistically significant difference was seen in overall rates of HO (47.7% vs 56.8%) or rates of grade II or more.[33] A similar finding was reported in a further randomized trial of 121 patients.[18] Indometacin once daily for 6 weeks was compared with placebo in patients with displaced fractures of the acetabulum reconstructed through a Kocher–Langenbeck approach. There was no statistically significant reduction in the incidence of severe (Brooker grade III–IV) HO with the use of indometacin compared with placebo (15.2% in the indometacin group and 19.4% for placebo). Based on the results, the authors now recommend against the use of indometacin for HO prophylaxis.[18,32] Problems of compliance with indometacin treatment have also been reported.[6,18] Overall, these data suggest that RT is more effective than NSAID, provided doses of $\geq$7 Gy are used.

This approach of using RT as prophylaxis against HO in high-risk surgical cases appears to be uncommon in the UK. In an informal survey, with responses from 30% of UK centres, no other centre is using RT is this way. One centre reported using RT as the HO prophylaxis after repair of fractures around the elbow, and 47% have used RT after revision hip surgery when HO is known to have occurred.

Overall, the results of this small series, especially the complete absence of any patients with severe HO, compare favourably with large published series.[2–10,13–15,17] They provide a context for estimates of risk and endorse our multidisciplinary approach of meticulous surgical reconstruction and post-operative RT. Where this is operationally or clinically impossible, 25 mg of

indometacin three times a day for 6 weeks has been used but is not favoured in older patients.

Estimating risk from radiotherapy

In this context, the major risk from RT is malignancy. The ICRP methodology,[25] with a risk factor of 4.1% per Sv for an adult population, provides an upper limit for the risk of fatal radiation-induced malignancy over the lifetime of the patient. Using this method, the estimated risk from RT for HO prophylaxis at the hip is around 0.092% or 1 in 1092 (Table 1). For practical purposes of patient information, rounding to a risk of 1 in 1000 is appropriate. This risk is delayed by an average of approximately 15 years.[34,35] However, the ICRP method is explicitly not intended for prediction of risks from therapeutic radiation.[25] It provides an estimate of global population risk, irrespective of age. It is also thought that the method may overestimate the risk, possibly by as much as 1–2 orders of magnitude.[26,27] Assuming the more conservative level of overestimate reduces the risk of RT-related death to 1 in 10,000, although it may be even lower. These figures provide estimates of the likely upper and lower limits of risk (Figure 3).

Another approach is to consider the number of cases of malignancy in patients treated with RT, for either malignant or benign tumours, although most series relate to treatment of malignancy. Although rare, the incidence of radiation-induced sarcoma (RIS) after RT, using high cancer treatment doses rather than low prophylaxis doses, has been estimated to be around 0.1% (*i.e.* 1 in 1000),[36] although it may be half that, 1 in 2000, in patients treated with megavoltage RT.[36] This is consistent with a report[37] of soft-tissue sarcomas ($n = 20$) and osteosarcomas ($n = 27$) arising in 38,000 patients treated with orthovoltage RT for a variety of benign and malignant conditions, including retinoblastoma, over 50 years. Ten of these arose in individuals treated as children. Interestingly, and relevant to the issue of HO prophylaxis, no cases occurred with doses <30 Gy.

There are two reports of RIS post-HO prophylaxis. One patient received 2×7 Gy and developed sarcoma after 18 years[38] and the second had a single 7 Gy and developed sarcoma after 11 years.[39] These reports are important but do not provide estimates of incidence since no denominator for unaffected cases is provided.

The method of Trott and Kamprad,[26] developed specifically for estimating cancer risks after RT for benign disease, is highly relevant. The main tissues at risk are the bone, the muscle and other soft tissues and the bone marrow. Taking the risk for RIS after treatment of benign disease as 1 in 100,000,[26] with the risk for induction of leukaemia as 1 in 3125 (assuming 2% of the bone marrow is exposed), and the leukaemia risk estimate as 0.2% per 1-Gy whole-marrow exposure[26] gives an estimated risk of 1 in 3000. This risk estimate falls within the range estimated above, using the ICRP methodology. Were there to be a small incidence of severe HO requiring surgery, the additional risk associated with surgery makes a negligible difference to these estimates.

The motivation for attempting to estimate risk was prompted by the recognition that some of the patients requiring consideration of RT prophylaxis are relatively young (Figure 1). Specifically, in our patient group, the mean age was 44 years, 15 (44%) patients were under 40 years, 5 (15%) were under 30 years and the youngest patient treated was only 21 years. This led to the additional need to evaluate risk for different ages at exposure, although this is notoriously difficult to assess. Few data are available from the National Research Council of the National Academies BEIR VII Phase 2 report.[29] The most relevant data are for "other" tumours, thus excluding central pelvic and thoracic tumours, and breast cancer, an important risk organ for whole-body exposure in females. Normalizing to our mean age of 44 years, the BEIR data suggest a small increase in risk for patients below 30 years and a large reduction in risk for older patients. Taking a risk of 1 in 3000 as the starting point, these numbers convert to 1 in 1900 or 1 in 6400 for a patient of 20 years or 70 years, respectively. For simplicity, these could be rounded to 1 in 2000 or 1 in 6000.

Estimating the risk from use of indometacin

Indometacin is the only drug proven to be effective against the development of HO following acetabular surgery. It is considered the gold standard NSAID for HO prophylaxis,[23,40] although other NSAIDs have been used,[30,31] and may be effective after hip arthroplasty.[40] There is some evidence of efficacy, as noted above, but this has not been consistently replicated.[18,31–33]

However, indometacin also appears to be amongst the most toxic of the NSAID drugs.[41] In their meta-analysis of NSAIDs, Fransen and Neal[30] identified 5% of patients to have experienced gastrointestinal toxicity, including 1.5% with serious toxicity. They were unable to comment on the risk of death. A separate review[42] reported that there was clear evidence that NSAIDs increase the early risk of upper gastrointestinal complications, suggesting that patients taking a short course are not to be

Table 1. Summary of risks of heterotopic ossification (HO) and range of estimates of risk of death, for the three prophylaxis strategies

Strategy	Risk of severe HO (grades III + IV)	Upper limit of estimate risk of death	Lower limit of estimate risk of death
Radiotherapy	0^a	1 in 1000	1 in 10,000
Indometacin	9–18% (1 in 11 to 1 in 6)	1 in 180	1 in 900
No prophylaxis	$12\%^b$ (1 in 8)	1 in 4000	1 in 30,000

[a]Addenbrooke's data (this series), and Kölbl et al.[5]
[b]For Kocher–Langenbeck surgical approach.

exempted. They also reported that "only" 2% of upper gastro-intestinal (GI) complications were recorded as being fatal. Indometacin is also associated with a risk of non-union in fractures away from the hip,[23,24] which is relevant for patients experiencing polytrauma such as occurs with RTAs.

Here, only risk of immediate death from intestinal perforation or haemorrhage will be considered, although other adverse effects occur and may be serious.[43,44] In patients aged 65 years and over who were admitted with peptic ulcer or upper GI bleeding following non-aspirin NSAID use, 53% had at least one serious complication and 11% required surgery.[45] The greatest risk was in the first month, a time frame analogous to HO prophylaxis. Patients of 60 years and over who used NSAIDs were 4.7 times more likely than non-users to die from ulcer disease.[46] In a meta-analysis of 16 studies on serious GI complications,[47] NSAID users were roughly three times more likely to have a serious GI complication than non-users, with an increased risk in patients of 60 years and over and in the first few weeks of administration. The overall prevalence of serious gastrointestinal complications was 1 per 1000 in the first year.[47]

Some of the reservations about indometacin were illustrated in a randomized prospective double-blind placebo-controlled clinical trial of the drug after the operative treatment of acetabular fractures.[18] Overall, 53% developed HO, which was severe in 17.3%. No significant difference in the incidence of HO was found between indometacin and placebo groups. However, 20% of the indometacin patients withdrew because of side effects, which were serious in 3% (one haemorrhage and one perforated ulcer). Compliance with the medication was also problematic, an issue also noted by others.[6] This, combined with the rate of complications, led the authors to terminate the study early and recommend against the use of indometacin in HO prophylaxis. Others have used misoprostol to aid in prevention of GI complications, although its routine use remains controversial.[44]

Taking a figure of 11% of patients (of 65 years or older) requiring surgery[45] and assuming a 1% perioperative mortality, gives an estimated mortality of 1 in 900 (Table 1). This assumes that every patient with life-threatening complications reaches the operating theatre alive. This risk is immediate and matches the figure for serious GI complications from Gabriel et al.[47] This is consistent with a risk of death of 2% in patients experiencing GI complications,[42] if about half of patients taking the drugs experience these.[45] Some sources suggest that the risk in emergency surgery for perforation or haemorrhage may be rather higher, in the range of 5–10%.[48,49] Taking a 5% figure increases the risk to 1 in 180, at least in patients aged over 60 years. The additional risk associated with surgery for HO resulting from failed indometacin prophylaxis makes little difference to these estimates.

In our series, 21% of patients were 60 years or over, and the oldest was a male aged 72 years. The risk in older patients is fairly clear, and remarkably high, even with short exposure. Unfortunately, data do not appear to exist (or be available) on risk at younger ages. Qualitatively, it appears to be less, perhaps

considerably less, than in older patients. Nevertheless, the efficacy of indometacin treatment may also be less than RT, and compliance remains a concern.

Estimating the risk from use of no prophylaxis
Although slightly artificial, a risk of death can be considered to exist for patients who develop severe HO, since a proportion may require further surgery to reduce morbidity, carrying a risk of perioperative death. In the meta-analysis, the overall risk of severe HO following surgery using the Kocher–Langenbeck approach was 11.6%.[17] The mean delay before reoperation was 2 years.[17] In another large series, 22.5% patients who developed severe HO required further surgery, with a mean interval of 24 months.[14] Combining these suggests that 2.6% of patients without prophylaxis (or with failed prophylaxis) would need reoperation. If the risk of perioperative death is 1%, this gives an upper limit of risk of around 1 in 4000 (Table 1). A systematic review of perioperative mortality[50] suggested an overall risk of perioperative death of 0.12%. Using this figure suggests a risk of around 1 in 30,000. This does not include the risk of malignancy from RT given as prophylaxis after second surgery, but since only 2.6% of patients are estimated to require second operation, this does not materially change the overall estimates.

Comparing risk estimates
These methods can achieve a population estimate of risk, within broad limits. The use of a range of risk acknowledges the uncertainty but at the same time provides at least approximate limits on the upper and lower values of risk. For RT prophylaxis, the risk estimates are in the range of 1 in 1000 to 1 in 10,000, and the treatment is effective (Table 1). The risk of developing severe HO after a posterior Kocher–Langenbeck surgical approach without prophylaxis is reported to be about 1 in 8. The risks associated with reoperation for severe HO are in the range of 1 in 4000 to 1 in 30,000, the exact figure depending on the mortality rate for elective surgery. These ranges overlap considerably, emphasizing their similarity and also indicating the difficulties in providing precise estimates of risk. The absolute risks are small, lower by several orders of magnitude than the lifetime risk from spontaneous cancer, which is about 1 in 3, and, assuming a global 50% cure rate, a risk of death of 1 in 6.

The risk associated with indometacin prophylaxis is rather high, at least in older patients. Some authors have reported stopping this form of treatment because of observed complications.[18] Our current work to estimate the risks of different approaches has influenced our practice such that we avoid indometacin wherever possible, and certainly in older patients.

This work was driven by the clinical need for us to evaluate our practice and also to provide information to patients considering RT prophylaxis. This was relevant for younger patients in whom RT risks might be larger and for older patients in whom indometacin risks might be higher. These results, together with the review of published work from large series, have allowed us to provide more balanced recommendations to patients and underpin our clinical protocol for multidisciplinary management.

CONCLUSIONS

Our clinical results of multidisciplinary management of patients with traumatic pelvic fractures are encouraging and compare well with published studies, with a minority of patients developing only grade I HO and none suffering severe grades. We attribute this to early intervention with meticulous surgical technique and reconstruction, followed by timely post-operative RT. Estimates of risk of death from fatal radiation-induced malignancy are in the range of 1 in 1000 to 1 in 10,000, with 1 in 3000 being a credible mid-range figure. For younger patients, this might rise to 1 in 2000, whereas for older patients, it may fall to 1 in 6000. This is substantially lower, by several orders of magnitude, than the lifetime risk of spontaneous cancer. Prophylaxis with indometacin is less effective with a higher risk of death from complications, of 1 in 900 or more. Omitting prophylaxis obviously carries the lowest estimated risk, in the range of 1 in 4000 to 1 in 30,000, but with a 1 in 8 risk of developing severe (grades III–IV) HO. Overall, the risk from RT prophylaxis is small, and the estimated range substantially overlaps with the range for no prophylaxis, suggesting it is safe as well as effective.

REFERENCES

1. Coventry MB, Scanlon PW. The use of radiation to discourage ectopic bone. A nine-year study in surgery about the hip. *J Bone Joint Surg Am* 1981; **63**: 201–8.

2. Sylvester JE, Greenberg P, Selch MT, Thomas BJ, Amstutz H. The use of postoperative irradiation for the prevention of heterotopic bone formation after total hip replacement. *Int J Radiat Oncol Biol Phys* 1988; **14**: 471–6.

3. Lo TC, Healy WL, Covall DJ, Dotter WE, Pfeifer BA, Torgerson WR, et al. Heterotopic bone formation after hip surgery: prevention with single-dose postoperative hip irradiation. *Radiology* 1988; **168**: 851–4. doi: 10.1148/radiology.168.3.3136510

4. Seegenschmiedt MH, Keilholz L, Martus P, Goldmann A, Wölfel R, Henning F, et al. Prevention of heterotopic ossification about the hip: final results of two randomized trials in 410 patients using either preoperative or postoperative radiation therapy. *Int J Radiat Oncol Biol Phys* 1997; **39**: 161–71.

5. Kölbl O, Knelles D, Barthel T, Kraus U, Flentje M, Eulert J. Randomized trial comparing early postoperative irradiation *vs* the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. *Int J Radiat Oncol Biol Phys* 1997; **39**: 961–6.

6. Moore KD, Goss K, Anglen JO. Indomethacin versus radiation therapy for prophylaxis against heterotopic ossification in acetabular fractures: a randomised, prospective study. *J Bone Joint Surg Br* 1998; **80**: 259–63.

7. Childs HA 3rd, Cole T, Falkenberg E, Smith JT, Alonso JE, Stannard JP, et al. A prospective evaluation of the timing of postoperative radiotherapy for preventing heterotopic ossification following traumatic acetabular fractures. *Int J Radiat Oncol Biol Phys* 2000; **47**: 1347–52.

8. Burd TA, Lowry KJ, Anglen JO. Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures. *J Bone Joint Surg Am* 2001; **83-A**: 1783–8.

9. Blokhuis TJ, Frölke JP. Is radiation superior to indomethacin to prevent heterotopic ossification in acetabular fractures?: a systematic review. *Clin Orthop Relat Res* 2009; **467**: 526–30. doi: 10.1007/s11999-008-0532-9

10. Mourad WF, Packianathan S, Shourbaji RA, Zhang Z, Graves M, Khan MA, et al. A prolonged time interval between trauma and prophylactic radiation therapy significantly increases the risk of heterotopic ossification. *Int J Radiat Oncol Biol Phys* 2012; **82**: e339–44.

11. Laird A, Keating JF. Acetabular fractures: a 16-year prospective epidemiological study. *J Bone Joint Surg Br* 2005; **87**: 969–73. doi: 10.1302/0301-620X.87B7.16017

12. Matta JM. Fractures of the acetabulum: accuracy of reduction and clinical results in patients managed operatively within three weeks after the injury. *J Bone Joint Surg Am* 1996; **78**: 1632–45.

13. Briffa N, Pearce R, Hill AM, Bircher M. Outcomes of acetabular fracture fixation with ten years' follow-up. *J Bone Joint Surg Br* 2011; **93**: 229–36.

14. Ghalambor N, Matta JM, Bernstein L. Heterotopic ossification following operative treatment of acetabular fracture. An analysis of risk factors. *Clin Orthop Relat Res* 1994: 96–105.

15. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. *J Bone Joint Surg Am* 1973; **55**: 1629–32.

16. Pohl F, Seufert J, Tauscher A, Lehmann H, Springorum HW, Flentje M, et al. The influence of heterotopic ossification on functional status of hip joint following total hip arthroplasty. *Strahlenther Onkol* 2005; **181**: 529–33.

17. Giannoudis PV, Grotz MR, Papakostidis C, Dinopoulos H. Operative treatment of displaced fractures of the acetabulum. A meta-analysis. *J Bone Joint Surg Br* 2005; **87**: 2–9.

18. Karunakar MA, Sen A, Bosse MJ, Sims SH, Goulet JA, Kellam JF. Indometacin as prophylaxis for heterotopic ossification after the operative treatment of fractures of the acetabulum. *J Bone Joint Surg Br* 2006; **88**: 1613–17. doi: 10.1302/0301-620X.88B12.18151

19. Pape HC, Marsh S, Morley JR, Krettek C, Giannoudis PV. Current concepts in the development of heterotopic ossification. *J Bone Joint Surg Br* 2004; **86**: 783–7.

20. Bhandari M, Matta J, Ferguson T, Matthys G. Predictors of clinical and radiological

outcome in patients with fractures of the acetabulum and concomitant posterior dislocation of the hip. *J Bone Joint Surg Br* 2006; **88**: 1618–24. doi: 10.1302/0301-620X.88B12.17309

21. Rath EM, Russell GV Jr, Washington WJ, Routt ML Jr. Gluteus minimus necrotic muscle debridement diminishes heterotopic ossification after acetabular fracture fixation. *Injury* 2002; **33**: 751–6.

22. Balboni TA, Gaccione P, Gobezie R, Mamon HJ. Shielding of the hip prosthesis during radiation therapy for heterotopic ossification is associated with increased failure of prophylaxis. *Int J Radiat Oncol Biol Phys* 2007; **67**: 1499–505. doi: 10.1016/j.ijrobp.2006.11.007

23. Baird EO, Kang QK. Prophylaxis of heterotopic ossification—an updated review. *J Orthop Surg Res* 2009; **4**: 12. doi: 10.1186/1749-799X-4-12

24. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. *J Bone Joint Surg Br* 2003; **85**: 700–5.

25. The 2007 recommendations of the International Commission on Radiological Protection. ICRP Publication 103 *Ann ICRP* 2007; **37**: 1–332.

26. Trott KR, Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. *Strahlenther Onkol* 2006; **182**: 431–6. doi: 10.1007/s00066-006-1542-8

27. Trott KR. Second cancers after radiotherapy. In: Joiner M, van der Kogel A, eds. *Basic clinical radiobiology*. 4th edn. London, UK: Hodder Arnold; 2009. pp. 339–52.

28. Mazonakis M, Berris T, Lyraraki E, Damilakis J. Cancer risk estimates from radiation therapy for heterotopic ossification prophylaxis after total hip arthroplasty. *Med Phys* 2013; **40**: 101702. doi: 10.1118/1.4820366

29. National Research Council of the National Academies. *Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2*. Washington, DC: The National Academies Press; 2006.

30. Fransen M, Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. *Cochrane Database Syst Rev* 2004; **3**: CD001160.

31. Zeckey C, Hildebrand F, Frink M, Krettek C. Heterotopic ossifications following implant surgery—epidemiology, therapeutical approaches and current concepts. *Semin Immunopathol* 2011; **33**: 273–86.

32. Griffin SM, Sims SH, Karunakar MA, Seymour R, Haines N. Heterotopic ossification rates after acetabular fracture surgery are unchanged without indomethacin prophylaxis. *Clin Orthop Relat Res* 2013; **471**: 2776–82.

33. Matta JM, Siebenrock KA. Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomised study. *J Bone Joint Surg Br* 1997; **79**: 959–63.

34. Mavrogenis AF, Pala E, Guerra G, Ruggieri P. Post-radiation sarcomas. Clinical outcome of 52 patients. *J Surg Oncol* 2012; **105**: 570–6. doi: 10.1002/jso.22122

35. Thariat J, Italiano A, Collin F, Iannessi A, Marcy PY, Lacout A, et al. Not all sarcomas developed in irradiated tissue are necessarily radiation-induced—spectrum of disease and treatment characteristics. *Crit Rev Oncol Hematol* 2012; **83**: 393–406. doi: 10.1016/j.critrevonc.2011.11.004

36. Amendola BE, Amendola MA, McClatchey KD, Miller CH Jr. Radiation-associated sarcoma: a review of 23 patients with postradiation sarcoma over a 50-year period. *Am J Clin Oncol* 1989; **12**: 411–15.

37. Kim JH, Chu FC, Woodard HQ, Melamed MR, Huvos A, Cantin J. Radiation-induced soft-tissue and bone sarcoma. *Radiology* 1978; **129**: 501–8. doi: 10.1148/129.2.501

38. Mourad WF, Packianathan S, Shourbaji RA, Russell G, Khan MA, Vijayakumar S. Radiation-induced sarcoma following radiation prophylaxis of heterotopic ossification. *Pract Radiat Oncol* 2012; **2**: 151–4. doi: 10.1016/j.prro.2011.06.005

39. Farris MK, Chowdhry VK, Lemke S, Kilpatrick M, Lacombe M. Osteosarcoma following single fraction radiation prophylaxis for heterotopic ossification. *Radiat Oncol* 2012; **7**: 140. doi: 10.1186/1748-717X-7-140

40. Macfarlane RJ, Ng BH, Gamie Z, El Masry MA, Velonis S, Schizas C, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. *Expert Opin Pharmacother* 2008; **9**: 767–86. doi: 10.1517/14656566.9.5.767

41. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. *Scand J Rheumatol Suppl* 1996; **102**: 3–8.

42. Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013; **382**: 769–79.

43. Sweetman SC, ed. *Martindale: the complete drug reference*. 37th edn. London, UK: Pharmaceutical Press; 2011.

44. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). *BMJ* 2013; **346**: f3195. doi: 10.1136/bmj.f3195

45. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. *Ann Intern Med* 1991; **114**: 257–63.

46. Griffin MR, Ray WA, Schaffner W. Non-steroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. *Ann Intern Med* 1988; **109**: 359–63.

47. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. *Ann Intern Med* 1991; **115**: 787–96.

48. Ellis H, Calne RY, Watson C. Chapter 21: the stomach and duodenum. In: *Lecture notes: general surgery*. 12th edn. Chichester, UK: Wiley-Blackwell; 2011. pp. 167–82.

49. Neary WD, Foy C, Heather BP, Earnshaw JJ. Identifying high-risk patients undergoing urgent and emergency surgery. *Ann R Coll Surg Engl* 2006; **88**: 151–6. doi: 10.1308/003588406X94896

50. Bainbridge D, Martin J, Arango M, Cheng D; Evidence-based Peri-operative Clinical Outcomes Research (EPiCOR) Group. Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis. *Lancet* 2012; **380**: 1075–81.